Brostallicin Demonstrates Antitumor Activity in Trial

Cell Therapeutics’ subsidiary Systems Medicine presented preliminary results of a Phase I trial combining cisplatin with brostallicin in patients with solid tumors that had relapsed or were resistant to front-line treatment.

Results from the first 21 patients treated showed that 14 patients experienced stable disease and seven had durable stable disease for more than six cycles of therapy, Cell Therapeutics reported.

Toxicities were mainly hematological and reversible. Phase II studies using this combination in patients resistant to standard therapy are planned.